Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects With HER2 Overexpressing Solid Tumors

Next Previous
Trial Profile

A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects With HER2 Overexpressing Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CT 0508 (Primary) ; CT 0508 (Primary) ; Filgrastim; Pembrolizumab
  • Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Gastric cancer; HER2 positive breast cancer; Oesophageal cancer; Ovarian cancer; Parotid cancer; Peritoneal disorders; Salivary gland cancer; Solid tumours; Testicular cancer; Uterine cancer
  • Focus Adverse reactions; First in man
  • Sponsors Carisma Therapeutics

Most Recent Events

  • 05 Nov 2024 According to a Carisma Therapeutics media release, data from the study will be presented in a poster session at the Society for Immunotherapy of Cancer ("SITC") Annual Meeting in Houston, Texas, on November 8, 2024.
  • 09 May 2024 According to a Carisma Therapeutics media release, , Due to the prioritization of CT-0525, Carisma has ceased recruitment of new patients into Study 101 and its sub-studies. However, the Company will continue all study operations for enrolled subjects.
  • 09 May 2024 According to a Carisma Therapeutics media release, Presented Regimen Level 1 data from Phase 1 sub-study utilizing CT-0508 in combination with pembrolizumab at AACR; expects to report Regimen Level 2 data in second quarter of 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top